JPRN-UMIN000004421
Completed
未知
Phase II study of lenalidomide consolidation/maintenance therapy after autologous stem cell transplantation in patients with symptomatic multiple myeloma. - JSCT-MM10
Japan Study Group for Cell Therapy and Transplantation0 sites37 target enrollmentOctober 20, 2010
ConditionsMultiple myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Multiple myeloma
- Sponsor
- Japan Study Group for Cell Therapy and Transplantation
- Enrollment
- 37
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Peripheral neuropathy (\>\=grade 2\) 2\.Prior high dose dexamethasone therapy caused severe adverse events as follows; Liver dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension, infection. 3\.Patient was suspected pneumonia (Interstitial pneumonia) by high dose dexamethasone therapy. (Consult a respiratory specialist if necessary) 4\.Those who are considered as inappropriate to register by attending physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Phase II study of Lenalidomide Maintenance after salvage therapy in patients with relapsed and/or refractory non-Hodgkin T-cell lymphomaNeoplasmsKCT0003593Samsung Medical Center79
Not yet recruiting
Not Applicable
lenalidomide maintenance in patients with primary central nervous system lymphomaNeoplasmsKCT0007015Seoul National University Bundang Hospital28
Not yet recruiting
Not Applicable
An Open-label, Phase 2 Study of lenalidomide Maintenance in Transplant-Ineligible Patients with Primary Central Nervous System LymphomaKCT0007409Yonsei University Health System, Severance Hospital35
Active, not recruiting
Not Applicable
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-camCLL patientsMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-001823-71-ITAssociazione Malattie Sangue ONLUS
Active, not recruiting
Phase 1
PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA - NDHistological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, c. nodal marginal zone lymphoma d. splenic marginal zone lymphomae. e. extranodal non-gastric marginal zone lymphomaMedDRA version: 9.1Level: LLTClassification code 10029463MedDRA version: 9.1Level: LLTClassification code 10003911MedDRA version: 9.1Level: LLTClassification code 10041652MedDRA version: 9.1Level: LLTClassification code 10025345EUCTR2008-001591-80-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI